Charlie Lees
3y ago
I write about Crohn's disease and ulcerative colitis (IBD), digital health, diet, genetics and the microbiome. I am a passionate educator and innovator. I am a gastroenterologist and I run a busy IBD clinic. I am a Professor of Gastroenterology running a research team improving outcomes for people living with IBD. For more content please see charlielees.com and search Charlie Lees at YouTube.
Crohn's disease and ulcerative colitis continue to rise globally, and there is an urgent unmet need for better prevention strategies and equitable access to expert care, latest medicines, nursing, dietary, and psychological support.
Raising Awareness: We need to raise awareness across all areas of society, including public, healthcare, policymakers, funders, and employers, globally.
Ensuring Equity of IBD Care: IBD affects anyone, with the highest incidence rates in younger people, who grow old with the disease. We need to ensure that everyone has access to high-quality IBD care regardless of their socioeconomic status, ethnicity, or location.
Stratification of Patients: We need better methods to individualise treatment choices, to avoid both over and under-treatment, and to identify those at risk from the complications of the disease and our therapies.
Precision Medicine: Holy grail or Loch Ness monster? With massive investments in large-scale single sequencing experiments and a high-throughput translational pipeline, I believe we will achieve it.
Breaking through the Therapeutic Ceiling: Despite the high effectiveness of many current therapies, we have reached something of a ceiling effect. Getting beyond this will require more targeted therapies, combinations of therapies, dietary and microbial therapies, and predictive tools
Microbial and Dietary Therapeutics: Longitudinal data in large cohorts will help us build the evidence basis around of diet and microbiome. New therapeutic strategies will follow, but require rigorous testing in the clinic.
Effective Therapies for Fistulas and Strictures: Both are associated with poor quality of life, lack effective medical treatment strategies and frequently necessitate surgical intervention.
Treating Patients Holistically: We need to invest in psychological support services and frameworks to deliver responsive care and manage fatigue, sleep disruption, family planning, intimacy, and dietary choices/restrictions.
Frictionless Monitoring Strategies: Innovative solutions that continuously monitor gut inflammation and predict flares will improve outcomes.
Prevention Strategies: To prevent IBD from developing in the first place requires identification of biomarkers of pre-clinical IBD and development of intervention strategies at the individual and societal level
The unmet need in IBD is substantial and urgent. By working together, we can bring hope to our global IBD community, ensure diversity in clinical trials and equity of clinical care, and improve outcomes for patients with IBD.